CLN8 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9UBY8 |
---|---|
Clone Names | 100324092 |
Gene ID | 2055 |
---|---|
Other Names | Protein CLN8, CLN8, C8orf61 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CLN8 |
---|---|
Synonyms | C8orf61 |
Function | Could play a role in cell proliferation during neuronal differentiation and in protection against cell death. |
Cellular Location | Endoplasmic reticulum membrane; Multi-pass membrane protein. Endoplasmic reticulum-Golgi intermediate compartment membrane; Multi-pass membrane protein. Endoplasmic reticulum |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a transmembrane protein belonging to afamily of proteins containing TLC domains, which are postulated tofunction in lipid synthesis, transport, or sensing. The proteinlocalizes to the endoplasmic reticulum (ER), and may recyclebetween the ER and ER-Golgi intermediate compartment. Mutations inthis gene are associated with progressive epilepsy with mentalretardation (EMPR), which is a subtype of neuronal ceroidlipofuscinoses (NCL). Patients with mutations in this gene havealtered levels of sphingolipid and phospholipids in the brain.
References
Reinhardt, K., et al. Clin. Genet. 77(1):79-85(2010)Vantaggiato, C., et al. Hum. Mutat. 30(7):1104-1116(2009)Kousi, M., et al. Brain 132 (PT 3), 810-819 (2009) :Striano, P., et al. Epilepsy Behav 10(1):187-191(2007)Hermansson, M., et al. J. Neurochem. 95(3):609-617(2005)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.